These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 6290819)

  • 1. Dopamine accumulation after dopamine beta-hydroxylase inhibition in rat heart as an index of norepinephrine turnover.
    Fuller RW; Snoddy HD; Perry KW
    Life Sci; 1982 Aug; 31(6):563-70. PubMed ID: 6290819
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Carbamazepine decreases catecholamine turnover in the rat brain.
    Waldmeier PC; Baumann PA; Fehr B; De Herdt P; Maitre L
    J Pharmacol Exp Ther; 1984 Oct; 231(1):166-72. PubMed ID: 6491972
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacological, hemodynamic and autonomic nervous system mechanisms responsible for the blood pressure and heart rate lowering effects of pergolide in rats.
    Cavero I; Lefevre-Borg F; Lhoste F; Sabatier C; Richer C; Giudicelli JF
    J Pharmacol Exp Ther; 1984 Mar; 228(3):779-91. PubMed ID: 6707926
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dopamine beta-hydroxylase inhibition reveals a selective influence of endotoxin on catecholamine content of rat tissues.
    Arnold J; Choo JJ; Little RA; Rothwell NJ
    Circ Shock; 1990 Aug; 31(4):387-94. PubMed ID: 2204497
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Some catecholamine inhibitors do not cause accumulation of nuclear estrogen receptors in rat hypothalamus and anterior pituitary gland.
    Blaustein JD; Brown TJ; McElroy JF
    Neuroendocrinology; 1986; 43(2):143-9. PubMed ID: 2873523
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Extracellular catecholamine levels in rat hippocampus after a selective alpha-2 adrenoceptor antagonist or a selective dopamine uptake inhibitor: evidence for dopamine release from local dopaminergic nerve terminals.
    Xu K; Näveri L; Frerichs KU; Hallenbeck JM; Feuerstein G; Davis JN; Sirén AL
    J Pharmacol Exp Ther; 1993 Oct; 267(1):211-7. PubMed ID: 7901393
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacological, hemodynamic and biochemical mechanisms involved in the blood pressure lowering effects of pergolide, in normotensive and hypertensive dogs.
    Cavero I; Lorrain J; Di Paola ED; Lhoste F; Payen B; Dennis T; Scatton B
    J Pharmacol Exp Ther; 1985 Dec; 235(3):798-809. PubMed ID: 2934543
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differences in the content and turnover of noradrenaline in rat heart atria and ventricles and circadian-phase-dependency.
    Lemmer B; Weimer R
    Experientia; 1983 Sep; 39(9):998-1000. PubMed ID: 6884497
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of LY104119, a thermogenic weight-reducing compound, on norepinephrine concentrations and turnover in obese and lean mice.
    Yen TT; Fuller RW; Hemrick-Luecke SK; Dininger NB
    Int J Obes; 1988; 12(1):59-67. PubMed ID: 2896179
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increased dopamine concentration in the striatum in the mouse by FLA-63, a dopamine- -hydroxylase inhibitor.
    Svensson TH
    J Pharm Pharmacol; 1973 Jan; 25(1):73-5. PubMed ID: 4146204
    [No Abstract]   [Full Text] [Related]  

  • 11. Noradrenergic terminals are the primary source of α
    Devoto P; Flore G; Saba P; Scheggi S; Mulas G; Gambarana C; Spiga S; Gessa GL
    Prog Neuropsychopharmacol Biol Psychiatry; 2019 Mar; 90():97-103. PubMed ID: 30472147
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Caffeine ingestion by rats increases noradrenaline turnover and results in self-biting.
    Miñana MD; Grisolía S
    J Neurochem; 1986 Sep; 47(3):728-32. PubMed ID: 2874191
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vivo inhibition of dopamine-beta-hydroxylase in rat adrenals during exposure to carbon disulphide.
    Caroldi S; Jarvis JA; Magos L
    Arch Toxicol; 1984 Oct; 55(4):265-7. PubMed ID: 6517704
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of dopamine-beta-hydroxylase inhibitors on blood pressure and cardiac norepinephrine levels in rats subjected to immobilization stress.
    Ishii Y; Mimura C; Homma M
    J Pharmacol Exp Ther; 1976 Sep; 198(3):589-95. PubMed ID: 988175
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Blood pressure decrease in spontaneously hypertensive rats folowing renal denervation or dopamine β-hydroxylase inhibition with etamicastat.
    Pires NM; Igreja B; Moura E; Wright LC; Serrão MP; Soares-da-Silva P
    Hypertens Res; 2015 Sep; 38(9):605-12. PubMed ID: 25854989
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Relationship between the antihypertensive activity of methyldopa and the appearance of its metabolites in the heart and brain of the hypertensive rat].
    Cohen Y; Wepierre J; Jacquot C; Rapin J
    Arch Int Pharmacodyn Ther; 1974 Feb; 207(2):348-60. PubMed ID: 4827419
    [No Abstract]   [Full Text] [Related]  

  • 17. Noradrenergic mediation of the positive reinforcing properties of ethanol: I. Suppression of ethanol consumption in laboratory rats following dopamine-beta-hydroxylase inhibition.
    Amit Z; Brown ZW; Levitan DE; Ogren SO
    Arch Int Pharmacodyn Ther; 1977 Nov; 230(1):65-75. PubMed ID: 603310
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of the beta-2 adrenergic agonist zinterol on norepinephrine turnover.
    O'Donnell JM
    Res Commun Chem Pathol Pharmacol; 1993 Apr; 80(1):113-6. PubMed ID: 8098163
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evidence for inhibition of dopamine-beta-hydroxylase in vivo after sub-acute pyrazole treatment in rats.
    MacDonald E; Pispa JP
    Med Biol; 1977 Oct; 55(5):284-91. PubMed ID: 22792
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of prazosin on norepinephrine concentration and turnover in rat brain and heart.
    Fuller RW; Snoddy HD; Perry KW
    Arch Int Pharmacodyn Ther; 1978 Jan; 231(1):30-41. PubMed ID: 637622
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.